Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent pulmonary fibrosis and identified a promising strategy to reverse it. The recent study published in…
Hyderabad: Drugmaker Dr. Reddy's Laboratories Limited has entered into an agreement to sell its entire shareholding in its wholly owned subsidiary, Svaas Wellness Limited, for a consideration of Rs 2.23…
New Delhi: Aurobindo Pharma Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in multiple strengths, the…
A new study has identified an association between consumption of drinks containing a high amount of sugar and anxiety symptoms in adolescents. Researchers at Bournemouth University were part of a…
New Delhi: Alembic Pharmaceuticals Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Dapagliflozin Tablets in strengths of 5 mg and 10 mg,…
A controversial class of drugs for Duchenne, Gilead's M&A streak, and more biotech news from The Readout
Netherlands: An open-label prospective study has found that approximately 26% of older adults were able to successfully discontinue levothyroxine under physician supervision while maintaining stable thyrotropin (TSH) and free thyroxine…
Immunoglobulin A (IgA) nephropathy is an autoimmune disease characterized by the deposition of circulating IgA-containing immune complexes (IgA-ICs) in the glomerular mesangium, leading to mesangial cell proliferation, enhanced extracellular matrix…
A new study published in Otolaryngology−Head and Neck Surgery, the peer-reviewed journal of the American Academy of Otolaryngology−Head and Neck Surgery Foundation (AAO-HNSF), finds that children with tympanostomy tubes who…
Researchers from the University of California San Diego have found that a novel blood-based biomarker can predict a woman’s risk of developing dementia as many as 25 years before symptoms…